ATOSSA THERAPEUTICS, INC.

ATOS · Nasdaq · United States

Share price · ATOS

$1.81-0.78 (-30.12%) 3M

close as of 2026-11-18 · 24h delayed · vol 44K (0.5x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when ATOS's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 4 Nov 2026-9.0%
  2. 19 Oct 2026-12.0%
  3. 16 Oct 2026+9.8%

    Nothing announced by ATOS that day or the session before.

  4. 13 Oct 2026+7.2%
  5. 1 Oct 2026+16.4%
  6. 11 Jun 2026-41.1%
  7. 11 Feb 2026-16.0%
  8. 2 Feb 2026-34.6%
  9. 16 Jan 2026+6.9%
  10. 14 Jan 2026-6.3%

    Nothing announced by ATOS that day or the session before.

Share of unusual movement by asset

For each asset, the share of ATOS's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
(Z)-endoxifen
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—3%
Other company news (earnings, financing, releases naming no asset)—36%
Sessions with no dated event—61%

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 2
Estrogen receptor (antagonist)Small molecule
Breast Cancer
HR+/HER2- Metastatic Breast Cancer

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
November 2026 (1)
(Z)-endoxifenPhase 2Breast Neoplasms, Invasive Breast Cancer, Estrogen-receptor-positive Breast Cancer, HER2-negative Breast Cancer
Est. primary completion 2026-11 · NCT05607004 · CT.gov ↗
What to watch
2028 (1)
June 2028 (1)
(Z)-endoxifenPhase 2Precocious Puberty, Gonadotropin-dependent
Est. primary completion 2028-06 · NCT07869732 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

14 May 2025Topline result(Z)-endoxifenI-SPY 2 EOP sub-study full results for low-dose (Z)-endoxifen

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$3.4M$21M$5.6M-$5.5M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$4.9M$26M$8.5M-$9.6M operating cash flowreport ↗
2026-Q1—$4.8M$32M$9.6M-$9.6M operating cash flowreport ↗
2025-Q3—$5.4M$52M$8.7M-$6.0M operating cash flowreport ↗
2025-Q2—$5.5M$58M$8.4M-$7.3M operating cash flowreport ↗
2025-Q1—$4.2M$65M$6.7M-$6.0M operating cash flowreport ↗
2024-Q3—$3.4M$75M$7.2M-$4.8M operating cash flowreport ↗
2024-Q2—$3.5M$80M$6.0M-$4.5M operating cash flowreport ↗
2024-Q1—$3.8M$84M$5.9M-$4.7M operating cash flowreport ↗
2023-Q3—$4.5M$94M$6.2M-$3.9M operating cash flowreport ↗
2023-Q2—$3.7M$99M$9.8M-$4.5M operating cash flowreport ↗
2023-Q1—$3.5M$104M$6.3M-$7.0M operating cash flowreport ↗
2022-Q3—$5.2M$117M$8.0M-$5.4M operating cash flowreport ↗
2022-Q2—$3.4M$126M$6.7M-$6.0M operating cash flowreport ↗
2022-Q1—$1.5M$131M$4.8M-$4.9M operating cash flowreport ↗
2021-Q3—$2.2M$140M$5.2M-$3.1M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$21M$41M$8.7M-$30M operating cash flowreport ↗

Atossa Therapeutics reported no revenue for fiscal 2025. R&D expenses were $21.19M, up 50.1% YoY from $14.12M, while cash and equivalents were $41.3M. The company recorded a net loss of $34.77M and a reported quarterly net burn of $34.77M.

The clinical-stage biopharma company is advancing oral (Z)-endoxifen across multiple Phase 2 trials, including Karisma, I-SPY 2, RECAST DCIS, and EVANGELINE. During the period, the FDA granted (Z)-endoxifen Rare Pediatric Disease and Orphan Drug designations for Duchenne muscular dystrophy. Management expects existing resources to fund operations for the next 12 months; the company also effected a 1-for-15 reverse stock split in February 2026 to regain Nasdaq compliance and entered into an at-the-market offering agreement for up to $50M.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$14M$71M$6.4M-$21M operating cash flowreport ↗
2023-FY—$17M$88M$7.5M-$21M operating cash flowreport ↗
2022-FY—$15M$111M$6.7M-$21M operating cash flowreport ↗
2021-FY—$9.2M$136M$5.2M-$16M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-05-12Cigler Tessa · directorAward / grant10,000——Form 4
2026-05-12Galli Stephen J · directorAward / grant10,000——Form 4
2026-05-12Finn Jonathan · directorAward / grant10,000——Form 4
2026-05-12Remmel H. Lawrence · directorAward / grant10,000——Form 4
2026-05-12Chen Shu-Chih · directorAward / grant10,000——Form 4
2026-05-12Steinhart Richard I · directorAward / grant10,000——Form 4
2026-03-27QUAY STEVEN C · director, President & CEOAward / grant65,000——Form 4
2026-03-26Daniel Mark James · Chief Financial OfficerAward / grant63,000——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 31 reporting institutions held 1.2M shares ($6.5M, 12.4% of shares outstanding).

#InstitutionSharesValue
1VANGUARD CAPITAL MANAGEMENT LLC349,096$1.8M
2AMERIPRISE FINANCIAL INC255,134$1.3M
3BlackRock, Inc.133,169$700K
4RENAISSANCE TECHNOLOGIES LLC109,007$573K
5GEODE CAPITAL MANAGEMENT, LLC97,061$511K
6UBS Group AG92,034$484K
7MILLENNIUM MANAGEMENT LLC66,739$351K
8VANGUARD FIDUCIARY TRUST CO52,235$275K
9STATE STREET CORP39,761$209K
10NORTHERN TRUST CORP19,224$101K
11MORGAN STANLEY16,202$85K
12Vanguard Global Advisers, LLC3,089$16K
13JONES FINANCIAL COMPANIES LLLP2,061$10K
14Tower Research Capital LLC (TRC)863$5K
15GROUP ONE TRADING LLC609$3K